Daré Bioscience DARE Stock
Daré Bioscience Price Chart
Daré Bioscience DARE Financial and Trading Overview
Daré Bioscience stock price | 2.88 USD |
Previous Close | 0.96 USD |
Open | 0.96 USD |
Bid | 0 USD x 900 |
Ask | 0 USD x 900 |
Day's Range | 0.96 - 0.97 USD |
52 Week Range | 0.82 - 1.47 USD |
Volume | 272.93K USD |
Avg. Volume | 192.65K USD |
Market Cap | 82.83M USD |
Beta (5Y Monthly) | 1.216549 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.48 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 5.28 USD |
DARE Valuation Measures
Enterprise Value | 63.53M USD |
Trailing P/E | N/A |
Forward P/E | -2.8235292 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 8.28334 |
Price/Book (mrq) | 16.551723 |
Enterprise Value/Revenue | 6.353 |
Enterprise Value/EBITDA | -2.027 |
Trading Information
Daré Bioscience Stock Price History
Beta (5Y Monthly) | 1.216549 |
52-Week Change | -21.95% |
S&P500 52-Week Change | 20.43% |
52 Week High | 1.47 USD |
52 Week Low | 0.82 USD |
50-Day Moving Average | 1 USD |
200-Day Moving Average | 1.02 USD |
DARE Share Statistics
Avg. Volume (3 month) | 192.65K USD |
Avg. Daily Volume (10-Days) | 257.58K USD |
Shares Outstanding | 86.28M |
Float | 84.62M |
Short Ratio | 1.98 |
% Held by Insiders | 1.92% |
% Held by Institutions | 8.52% |
Shares Short | 342.64K |
Short % of Float | 0.40% |
Short % of Shares Outstanding | 0.40% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor | 1:10 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -313.67% |
Gross Margin | 99.00% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -49.28% |
Return on Equity (ttm) | -170.66% |
Income Statement
Revenue (ttm) | 10M USD |
Revenue Per Share (ttm) | 0.12 USD |
Quarterly Revenue Growth (yoy) | N/A |
Gross Profit (ttm) | 9.9M USD |
EBITDA | -31339204 USD |
Net Income Avi to Common (ttm) | -30591568 USD |
Diluted EPS (ttm) | -0.35 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 19.83M USD |
Total Cash Per Share (mrq) | 0.23 USD |
Total Debt (mrq) | 392.89K USD |
Total Debt/Equity (mrq) | 7.9 USD |
Current Ratio (mrq) | 1.213 |
Book Value Per Share (mrq) | 0.058 |
Cash Flow Statement
Operating Cash Flow (ttm) | -21862528 USD |
Levered Free Cash Flow (ttm) | -10664284 USD |
Profile of Daré Bioscience
Country | United States |
State | CA |
City | San Diego |
Address | 3655 Nobel Drive |
ZIP | 92122 |
Phone | (858) 926-7655 |
Website | https://www.darebioscience.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 25 |
Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company's product includes XACIATO, a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older. Its products in advanced clinical development include Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder; and DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy. The company's Phase I-ready products are DARE-VVA1, a proprietary formulation of tamoxifen for intravaginal to treat vulvar vaginal atrophy in women with hormone-receptor positive breast cancer; DARE-PDM1, a proprietary hydrogel formulation of diclofenac, a nonsteroidal anti-inflammatory drug, for vaginal administration as a treatment for dysmenorrhea; DARE-204 and DARE-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for broader luteal phase support as part of an in vitro fertilization treatment plan, as well as DARE-PTB1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth. Its products in pre-clinical stage include DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-GML, an intravaginally-delivered potential multi-target antimicrobial agent formulated with glycerol monolaurate; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; and DARE-RH1, a non-hormonal contraception for men and women. The company entered into license agreement with Organon & Co. and Organon International GmbH to commercialize XACIATO. Daré Bioscience, Inc. is headquartered in San Diego, California.
Q&A For Daré Bioscience Stock
What is a current DARE stock price?
Daré Bioscience DARE stock price today per share is 2.88 USD.
How to purchase Daré Bioscience stock?
You can buy DARE shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Daré Bioscience?
The stock symbol or ticker of Daré Bioscience is DARE.
Which industry does the Daré Bioscience company belong to?
The Daré Bioscience industry is Biotechnology.
How many shares does Daré Bioscience have in circulation?
The max supply of Daré Bioscience shares is 8.7M.
What is Daré Bioscience Price to Earnings Ratio (PE Ratio)?
Daré Bioscience PE Ratio is now.
What was Daré Bioscience earnings per share over the trailing 12 months (TTM)?
Daré Bioscience EPS is -0.48 USD over the trailing 12 months.
Which sector does the Daré Bioscience company belong to?
The Daré Bioscience sector is Healthcare.
Daré Bioscience DARE included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NASDAQ Composite IXIC | 15574.35 USD — |
-0.09
|
6.67B USD — | 14784.03 USD — | 16292.28 USD — | — - | 6.67B USD — |
NASDAQ Capital Market Composite RCMP | 92.17 USD — |
+0.01
|
— — | 86.91 USD — | 95.14 USD — | — - | — — |
NASDAQ HealthCare IXHC | 863.86 USD — |
-0.68
|
— — | 828.4 USD — | 890 USD — | — - | — — |
- {{ link.label }} {{link}}